{
  "docId": "019de074-f3a0-71ae-8e30-38333965b689",
  "docSlug": "e090e5c29fca7648cb88dae8fea2c1eb",
  "documentTitle": "Kiromic BioPharma | Investor Presentation Deck | 25 slides",
  "authorId": "kiromic-biopharma",
  "authorName": "Kiromic BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 20,
  "pageCount": 25,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "timeline",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 5,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-f3a0-71ae-8e30-38333965b689/20",
  "deckHref": "/decks/019de074-f3a0-71ae-8e30-38333965b689",
  "deckJsonHref": "/decks/019de074-f3a0-71ae-8e30-38333965b689.json",
  "deckAnchorHref": "/decks/019de074-f3a0-71ae-8e30-38333965b689#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.71,
        "x": 0.056,
        "y": 0.805
      },
      "kind": "disclaimer",
      "text": "*The milestones and timing of completion are based upon the company's current expectations in consultation with its partners and vendors.\n** Subject to sufficient financing to support the progression of the development of those additional clinical trial candidates..",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72f1214f-4f20-46c0-9d3c-2a6e8bd9e03d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.92,
        "x": 0.042,
        "y": 0.245
      },
      "kind": "list",
      "text": "1. IND AUTHORIZATION TO EVALUATE DELTACEL IN NON-SMALL CELL LUNG CANCER - MAY 1, 2023\n2. Beginning of First in-Human Trial Activation for Deltacel - Q2 2023\n3. Data Results from First Patient in Deltacel Clinical Trial - By End of Q4 2023\n4. Initiation of Clinical Trials Expansion Cohort - H2 2024\n5. Submission of new INDs for Procel and Isocel - H1 2025**",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b939b8f4-0ad4-40e8-a2d7-f4c7b322df98",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.315,
        "x": 0.038,
        "y": 0.158
      },
      "kind": "title",
      "text": "Upcoming Milestones*",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8433fafe-a63d-44f2-a569-e898bc232fcb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "483449dd-51b6-4ed8-9485-5c64bbc130fc",
      "evidence": "Sequential list of future events with dates",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}